Key Events This Week
May 4: Bearish technical shift noted amid mixed momentum signals
May 5-7: Consecutive strong price gains with rising volumes
May 8: Mixed quarterly results reported, stock closes lower
May 29
BSE+NSE Vol: 3.46 lacs

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
May 4: Bearish technical shift noted amid mixed momentum signals
May 5-7: Consecutive strong price gains with rising volumes
May 8: Mixed quarterly results reported, stock closes lower
Shukra Pharmaceuticals Ltd's latest financial results for the quarter ending March 2026 reveal significant operational challenges. The company's net sales experienced a dramatic decline of approximately 83.85% quarter-on-quarter, dropping to ₹6.32 crores from ₹39.13 crores in the previous quarter. This steep fall raises concerns about revenue recognition practices and suggests potential volatility in the company's operational performance. In terms of profitability, Shukra Pharmaceuticals reported a net loss of ₹1.72 crores for the quarter, which reflects a substantial decline compared to the previous quarter's profit. The operating margin also contracted sharply to 11.08%, down from an exceptionally high 69.33% in the prior quarter. This compression in margins indicates a significant shift in the company's cost structure or product mix, which may have been influenced by pricing pressures or changes in dema...
Read full news article
Shukra Pharmaceuticals Ltd. reported a challenging fourth quarter for FY26, with net profit swinging to a loss of ₹1.72 crores from a profit of ₹5.39 crores in the same period last year, marking a sharp 154.43% year-on-year decline. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,469 crores, saw its stock decline 4.99% to ₹33.54 following the results announcement, as investors reacted to the dramatic quarterly reversal despite strong half-yearly performance.
Read full news article
Shukra Pharmaceuticals Ltd has experienced a notable shift in its financial trend, moving from an outstanding to a positive performance rating in the latest quarter ending March 2026. Despite strong half-yearly sales and profit after tax (PAT) figures, the company’s most recent quarterly results reveal significant declines in revenue and profitability compared to its previous four-quarter averages, prompting a downgrade in its Mojo Grade from Hold to Sell.
Read full news article
Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a shift in its technical momentum, moving from a mildly bearish to a bearish trend. Despite a modest day change of 0.03%, the stock’s technical indicators reveal a complex picture with mixed signals across weekly and monthly timeframes, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026.
Read full news article
Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 May 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleNewspaper publication of Standalone Audit Financial Results for Fourth Quarter and Financial Year ended on 31st March 2026
the board has recommended and declared the dividend of Rs. 0.01/- (1%)
Regulation 24A for the period ended march 31 2026
No Upcoming Board Meetings
Shukra Pharmaceuticals Ltd has declared 1% dividend, ex-date: 18 Sep 25
Shukra Pharmaceuticals Ltd has announced 1:10 stock split, ex-date: 21 Mar 25
Shukra Pharmaceuticals Ltd has announced 3:1 bonus issue, ex-date: 19 Apr 24
Shukra Pharmaceuticals Ltd has announced 6:1 rights issue, ex-date: 02 Feb 23